Who
Patrick Machado
Director
Company insider
Files Form 4 as: Director, Alumis; Director, Arcus Biosciences; Director, Xenon Pharmaceuticals; Director, Adverum Biotechnologies; Director, Acelyrin; Director, Chimerix; Director, Turning Point Therapeutics; Director, Principia Biopharma.
In numbers
- Trades disclosed
- 336
- Buys
- 35
- Sells
- 45
- Bought
- $126.7M
- Sold
- $54.6M
- Companies
- 16
- Companies where not an officer
- 15
- First trade
- 5 Apr 2005
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Code A | —3,553 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,528 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,528 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Code A | —3,553 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —5,700 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,900 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,900 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —5,700 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —1,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —6,476 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —3,360 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —3,500 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.